Statement of Financial Position as at 31 March 2025

Figures in Rand	Notes	2025	2024
Assets			
Non-Current Assets			
Property, plant and equipment	4	145 787	95 407
Right-of-use assets	5	1 235 610	2 218 025
Intangible assets	6	61 579 506	49 475 783
Deferred tax	7	3 273 395	2 021 033
		66 234 298	**53 810 248**
Current Assets			
Inventories	8	117 875 141	86 909 902
Trade and other receivables	9	132 761 850	136 748 899
Cash and cash equivalents	10	68 105 230	52 532 432
		318 742 221	**276 191 233**
Total Assets		**384 976 519**	**330 001 481**
Equity and Liabilities			
Equity			
Share capital	11	27 598 117	27 598 117
Cashflow Hedge Reserves		(1 654 377)	(1 654 611)
Retained income		282 051 394	240 429 498
		307 995 134	**266 373 004**
Liabilities			
Non-Current Liabilities			
Lease liabilities	5	319 845	1 534 683
Current Liabilities			
Trade and other payables	13	68 857 792	56 237 122
Lease liabilities	5	1 214 838	1 085 488
Current tax payable		1 335 461	225 893
Provisions	12	5 253 449	4 545 291
		76 661 540	**62 093 794**
Total Liabilities		**76 981 385**	**63 628 477**
Total Equity and Liabilities		**384 976 519**	**330 001 481**

Statement of Profit or Loss and Other Comprehensive Income

Figures in Rand	Notes	2025	2024
Revenue	14	534 520 669	540 210 756
Cost of sales	15	(287 674 944)	(346 662 813)
Gross profit		**246 845 725**	**193 547 943**
Sundry income	16	4 183 302	3 289 289
Other operating expenses		(200 092 691)	(159 011 071)
Operating profit	18	**50 936 336**	**37 826 161**
Investment income	20	6 884 014	5 794 964
Finance costs	21	(142 342)	(273 669)
Profit before taxation		**57 678 008**	**43 347 456**
Taxation	22	(16 056 112)	(11 732 968)
Profit for the year		**41 621 896**	**31 614 488**
Other comprehensive income:			
Items that may be reclassified to profit or loss:			
Gains (losses) on cash flow hedges not subject to basis adjustments		320	(2 266 587)
Income tax relating to items that may be reclassified		(86)	611 979
Total items that may be reclassified to profit or loss		**234**	**(1 654 608)**
Other comprehensive income for the year net of taxation		**234**	**(1 654 608)**
Total comprehensive income for the year		**41 622 130**	**29 959 880**

Statement of Changes in Equity

Figures in Rand	Share capital	Share premium	Total share capital	Cash flow hedging reserve	Retained income	Total equity
Balance at 01 April 2023	**4 701**	**27 593 416**	**27 598 117**	**-**	**208 815 010**	**236 413 127**
Profit for the year	-	-	-	-	31 614 488	31 614 488
Other comprehensive income	-	-	-	(1 654 611)	-	(1 654 611)
Total comprehensive income for the year	**-**	**-**	**-**	**(1 654 611)**	**31 614 488**	**29 959 877**
Balance at 01 April 2024	**4 701**	**27 593 416**	**27 598 117**	**(1 654 611)**	**240 429 498**	**266 373 004**
Profit for the year	-	-	-	-	41 621 896	41 621 896
Other comprehensive income	-	-	-	234	-	234
Total comprehensive income for the year	**-**	**-**	**-**	**234**	**41 621 896**	**41 622 130**
Balance at 31 March 2025	**4 701**	**27 593 416**	**27 598 117**	**(1 654 377)**	**282 051 394**	**307 995 134**
Note	11&12	11	11			

Biotech Laboratories (Pty) Ltd

(Registration number 1990/007220/07)
Financial Statements for the year ended 31 March 2025

Statement of Cash Flows

Figures in Rand	Note(s)	2025	2024
Cash flows from operating activities			
Cash generated from operations	23	42 597 896	25 767 455
Interest income	20	6 884 014	5 794 964
Finance costs	21	(142 342)	(273 669)
Tax paid	24	(14 946 544)	(10 505 222)
Net cash from operating activities		**34 393 024**	**20 783 528**
Cash flows from investing activities			
Purchase of property, plant and equipment	4	(126 472)	(27 550)
Purchases of intangible assets	6	(17 338 555)	(7 118 465)
Purchases of investments in subsidiaries, associates or joint arrangements		320	-
Net cash from investing activities		**(17 464 707)**	**(7 146 015)**
Cash flows from financing activities			
Cash repayments on lease liabilities	5	(1 085 488)	(943 213)
Total cash movement for the year		**15 842 829**	**12 694 300**
Cash and cash equivalents at the beginning of the year		52 532 432	39 838 132
Cash and cash equivalents at the end of the year	10	**68 375 261**	**52 532 432**